FDA approves Eisai’s epilepsy drug for partial-onset seizures

The Food and Drug Administration on Wednesday approved Eisai’s epilepsy drug Fyompa as a primary treatment for partial-onset seizures in epileptic patients 12 years or older.

Advertisement
By: Mackenzie Bean

Here are three things to know.

  1. Fycompa is a once-daily tablet patients take before bed.
  1. The agency first approved Fyompa in 2012 as an adjunct therapy for partial-onset seizures. The drug can now be used as a sole treatment for the condition.
  1. The drug acts as an agonist to limit the overstimulation of neurons associated with seizures.

More articles on supply chain:

6 must-reads for supply chain leaders this week
Tip: Time back through supply chain workflow optimization
Intermountain adopts needle-free technology for blood draws

Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit

Advertisement

Next Up in Supply Chain

Advertisement

Comments are closed.